{"id":34806,"date":"2025-06-05T20:14:02","date_gmt":"2025-06-05T12:14:02","guid":{"rendered":"https:\/\/flcube.com\/?p=34806"},"modified":"2025-06-05T20:14:03","modified_gmt":"2025-06-05T12:14:03","slug":"innovent-biologics-ibi363-receives-breakthrough-therapy-designation-from-cde","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34806","title":{"rendered":"Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE"},"content":{"rendered":"\n

China-based Innovent Biologics, Inc. (HKG: 1801<\/a>) announced that its first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion protein, IBI363, has received breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed after platinum-based chemotherapy and anti-PD-1\/PD-L1 immunotherapy.<\/p>\n\n\n\n

Clinical Data and Previous Designations<\/strong>
IBI363 has demonstrated positive clinical data in treating patients with immune-resistant cold tumors, including non-small cell lung cancer, colorectal cancer, and melanoma. These results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Additionally, the drug previously received fast track designation from the US Food and Drug Administration (FDA) for use in melanoma.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion…<\/p>\n","protected":false},"author":1,"featured_media":34808,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,910,198,28],"class_list":["post-34806","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-hkg-1801","tag-innovent-biologics","tag-multi-specific-antibodies"],"yoast_head":"\nInnovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion protein, IBI363, has received breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed after platinum-based chemotherapy and anti-PD-1\/PD-L1 immunotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34806\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE\" \/>\n<meta property=\"og:description\" content=\"China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion protein, IBI363, has received breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed after platinum-based chemotherapy and anti-PD-1\/PD-L1 immunotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34806\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-05T12:14:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-05T12:14:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0514.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE\",\"datePublished\":\"2025-06-05T12:14:02+00:00\",\"dateModified\":\"2025-06-05T12:14:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806\"},\"wordCount\":136,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0514.webp\",\"keywords\":[\"Breakthrough therapy\",\"HKG: 1801\",\"Innovent Biologics\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34806#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34806\",\"name\":\"Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0514.webp\",\"datePublished\":\"2025-06-05T12:14:02+00:00\",\"dateModified\":\"2025-06-05T12:14:03+00:00\",\"description\":\"China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1\\\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion protein, IBI363, has received breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed after platinum-based chemotherapy and anti-PD-1\\\/PD-L1 immunotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34806\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0514.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0514.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34806#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE - Insight, China's Pharmaceutical Industry","description":"China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion protein, IBI363, has received breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed after platinum-based chemotherapy and anti-PD-1\/PD-L1 immunotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34806","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE","og_description":"China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion protein, IBI363, has received breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed after platinum-based chemotherapy and anti-PD-1\/PD-L1 immunotherapy.","og_url":"https:\/\/flcube.com\/?p=34806","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-05T12:14:02+00:00","article_modified_time":"2025-06-05T12:14:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0514.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34806#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34806"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE","datePublished":"2025-06-05T12:14:02+00:00","dateModified":"2025-06-05T12:14:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34806"},"wordCount":136,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34806#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0514.webp","keywords":["Breakthrough therapy","HKG: 1801","Innovent Biologics","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34806#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34806","url":"https:\/\/flcube.com\/?p=34806","name":"Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34806#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34806#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0514.webp","datePublished":"2025-06-05T12:14:02+00:00","dateModified":"2025-06-05T12:14:03+00:00","description":"China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1\/IL-2\u03b1-bias bispecific antibody (BsAb) fusion protein, IBI363, has received breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed after platinum-based chemotherapy and anti-PD-1\/PD-L1 immunotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34806#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34806"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34806#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0514.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0514.webp","width":1080,"height":608,"caption":"Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34806#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0514.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34806"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34806\/revisions"}],"predecessor-version":[{"id":34809,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34806\/revisions\/34809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34808"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}